Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.49 |
| ▸ | CDK7 | P50613 | 10/20 | 0.47 |
| ▸ | CDK9 | P50750 | 10/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | NPM1 | P06748 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31471890 | 1.00 | ALK (0.49) | ALKCDK7CDK9TTKINSR | |
| SCHEMBL14866187 | 0.88 | MEN1 (0.42) | ALKCDK7CDK9TTKINSR | |
| SCHEMBL14866229 | 0.88 | ALK (0.42) | ALKCDK7CDK9TTKINSR | |
| SCHEMBL14866243 | 0.88 | ALK (0.46) | ALKCDK7CDK9TTKINSR | |
| SCHEMBL14866327 | 0.84 | MAPT (0.48) | ALKINSRNPM1ROS1EGFR | |
| SCHEMBL14866248 | 0.84 | MAPT (0.46) | ALKINSRNPM1ROS1EGFR | |
| SCHEMBL14866264 | 0.84 | PDE5A (0.49) | ALKPDE5A | |
| SCHEMBL14866185 | 0.84 | ALK (0.49) | ALKCDK7CDK9ROS1EGFR | |
| SCHEMBL3959009 | 0.82 | ALK (0.51) | ALKCDK7CDK9TTKROS1 | |
| SCHEMBL20887600 | 0.82 | TTK (0.66) | ALKCDK7CDK9TTKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885CDK7 2676/4885CDK9 1382/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885CDK7 2676/4885CDK9 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.